A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KZR-616 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2017
At a glance
- Drugs KZR 616 (Primary) ; KZR 616 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors Kezar Life Sciences
- 25 Jul 2017 According to a Kezar Life Sciences media release, additional results from the study are anticipated to be presented at the American College of Rheumatology's Annual Meeting in San Diego in November.
- 25 Jul 2017 Results published in a Kezar Life Sciences media release.
- 25 Jul 2017 According to a Kezar Life Sciences media release, the company has completed phase Ia portion of the study.